Sigvion Ventures

Sigvion is a pre-clinical stage biotechnology company focused on developing next-generation non-viral delivery systems for nucleic acid therapeutics. The company's proprietary platform utilizes hybrid nanoparticles designed to safely and efficiently deliver mRNA, siRNA, and DNA payloads to targeted tissues, addressing the limitations of current viral and lipid-based delivery methods. Sigvion's technology is particularly aimed at treating complex diseases such as triple-negative breast cancer and various rare genetic disorders. By enhancing the stability and precision of genetic medicine delivery, the company seeks to enable a new class of highly effective, low-toxicity treatments that can reach previously inaccessible biological targets.